Analytical Data
-
Gene name
GRPR
- Application
-
Alternative Names
GRPR；Gastrin-releasing peptide receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30550
-
Expression Region
1-384aa
-
AA Sequence
MALNDCFLLNLEVDHFMHCNISSHSADLPVNDDWSHPGILYVIPAVYGVI ILIGLIGNITLIKIFCTVKSMRNVPNLFISSLALGDLLLLITCAPVDASR YLADRWLFGRIGCKLIPFIQLTSVGVSVFTLTALSADRYKAIVRPMDIQA SHALMKICLKAAFIWIISMLLAIPEAVFSDLHPFHEESTNQTFISCAPYP HSNELHPKIHSMASFLVFYVIPLSIISVYYYFIAKNLIQSAYNLPVEGNI HVKKQIESRKRLAKTVLVFVGLFAFCWLPNHVIYLYRSYHYSEVDTSMLH FVTSICARLLAFTNSCVNPFALYLLSKSFRKQFNTQLLCCQPGLIIRSHS TGRSTTCMTSLKSTNPSVATFSLINGNICHERYV
-
Molecular Weight
68 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Gastrin-releasing peptide receptor (GRPR) is a member of the bombesin receptor family and is primarily known for its role in various physiological processes, including the regulation of gastrin release and modulation of gastric motility. GRPR has garnered significant attention in cancer research, particularly due to its overexpression in several malignancies, including prostate, breast, and non-small cell lung cancers. This overexpression presents GRPR as a promising target for novel diagnostic and therapeutic strategies. In recent years, the development of GRPR-targeted imaging and therapy, utilizing radiolabeled peptides and small molecules, has shown potential in improving tumor visualization and treatment effectiveness. Furthermore, GRPR is implicated in neurogenic inflammation and the central nervous system's regulation, paving the way for research on its role in neurological disorders. Investigating GRPR and its signaling pathways may lead to breakthroughs in understanding tumor biology and enhancing targeted therapies, thereby offering new hope for patients suffering from GRPR-expressing cancers. As a result, GRPR-based research continues to expand, aiming to uncover its full potential in clinical applications and improve patient outcomes.
